<DOC>
	<DOCNO>NCT01100164</DOCNO>
	<brief_summary>The primary objective study determine whether eszopiclone ( Eurofarma ) non-inferior reference drug zopiclone ( Imovane® , Sanofi-Aventis ) treatment insomnia .</brief_summary>
	<brief_title>A Non-inferiority Study With Two Treatment Arms Eszopiclone 3 mg Versus Zopiclone 7.5 mg - Treatment Insomnia</brief_title>
	<detailed_description>The primary objective study determine whether eszopiclone ( Eurofarma ) non-inferior reference drug zopiclone ( Imovane® , Sanofi-Aventis ) treatment insomnia . To end , latency persistent sleep ( LPS ) use primary endpoint end treatment , measure polysomnography . The secondary objective endpoint study follow : - To evaluate efficiency eszopiclone compare zopiclone mean patient 's clinical history , use secondary endpoint : - Variables sleep diary Associação Fundo de Incentivo à Psicofarmacologia ( see Appendix A ) , namely : - Latency time begin sleep ; - Frequency night wake-ups ; - Time awake bedtime ; - Early morning awakening ; - Total time bed ; - Sleep efficiency ; - Sleep variable measure actigraph ; - Insomnia Severity Index ( see Appendix B ) ; 45 - Pittsburgh Sleep Quality Index ( see Appendix C ) ; 46 - To evaluate safety eszopiclone compare zopiclone mean adverse event study arm .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Eszopiclone</mesh_term>
	<mesh_term>Zopiclone</mesh_term>
	<criteria>Sign inform consent form study ; Be ≥ 20 ≥ 64 year old ; Have diagnosis symptomatic primary insomnia least 3 month ; Have polysomnography conduct least 90 day inclusion study sleep time le 6.5 hour sleep latency ≥ 20 minute ; Be able take insomnia medication 14 day randomization study ( washout period ) . Diagnosis sleep disorder polysomnography conduct 90 day inclusion study ; Use medication affect sleep , psychotropic , hypnotic antihistamine agent least 15 day inclusion study ; Use herbal supplement insomnia melatonin 14 day enter study ; Current use liver metabolize medication , especially metabolize cytochrome P450 enzyme complex , especially CYP3A4 and/or CYP2E1 route ; History daily use alcohol beverage quantity equivalent ethanol standpoint two can beer day ( 35 g alcohol/day ) ; History substance abuse dependence ; Patients severe comorbidities ( investigator 's opinion ) ; Presence liver disorder , cirrhosis liver failure ; Presence psychiatric disorder diagnose adult life currently treatment ; Pregnant breastfeed woman woman want become pregnant study period refuse use proper contraceptive method study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>INSOMNIA</keyword>
	<keyword>FOR THE TREATMENT OF INSOMNIA</keyword>
</DOC>